TY - JOUR
T1 - Genome-based diagnostics and therapeutics in personalized cancer therapy
T2 - Can the challenges be overcome?
AU - Ajani, J.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/4
Y1 - 2012/4
N2 - With isolated success - trastuzumab, imatinib, vemurafenib-, the current generation of targeted drugs provides limited benefit for cancer patients. Evidence from phase 3 randomized trials suggests mostly progression-free survival benefit without a true overall survival prolongation. The advent of high-throughput technologies and advances in systems computational biology shape now high expectations for the next-generation cancer-targeted drugs and biomarkers. This new era of personalized medicine raises hope for individual tumor-heterogeneity-based implementation of targeted drugs. Which are the challenges and how could be possible to overcome therapeutic resistance of cancer cells and to increase cancer therapy efficacy and improve oncological outcomes?
AB - With isolated success - trastuzumab, imatinib, vemurafenib-, the current generation of targeted drugs provides limited benefit for cancer patients. Evidence from phase 3 randomized trials suggests mostly progression-free survival benefit without a true overall survival prolongation. The advent of high-throughput technologies and advances in systems computational biology shape now high expectations for the next-generation cancer-targeted drugs and biomarkers. This new era of personalized medicine raises hope for individual tumor-heterogeneity-based implementation of targeted drugs. Which are the challenges and how could be possible to overcome therapeutic resistance of cancer cells and to increase cancer therapy efficacy and improve oncological outcomes?
UR - http://www.scopus.com/inward/record.url?scp=84860495580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860495580&partnerID=8YFLogxK
U2 - 10.2122/gbc.2012.0222
DO - 10.2122/gbc.2012.0222
M3 - Review article
AN - SCOPUS:84860495580
SN - 1109-7655
VL - 11
SP - 53
EP - 57
JO - Gastric and Breast Cancer
JF - Gastric and Breast Cancer
IS - 2
ER -